PMID- 11356903
OWN - NLM
STAT- MEDLINE
DCOM- 20010614
LR  - 20131121
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 297
IP  - 3
DP  - 2001 Jun
TI  - 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor 
      function and serotonin-dopamine interactions.
PG  - 846-52
AB  - (+)-3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy"; "X"; "E") is a popular 
      recreational amphetamine analog that produces a unique set of effects in humans 
      and animals. MDMA use is often associated with dance parties called "raves", but 
      its use has increased in all segments of society and around the world. Like 
      amphetamine, MDMA elicits hyperactivity when administered to rodents. Unlike 
      amphetamine, which has effects mediated by the release of dopamine (DA) from 
      nerve terminals, MDMA-induced hyperactivity is thought to be dependent upon the 
      release of 5-hydroxtryptamine (5-HT). However, MDMA elicits large increases in 
      synaptic concentrations of both DA and 5-HT, and the interaction between these 
      neurotransmitters may account for the unique characteristics of the drug. 
      Comparisons between MDMA, the selective DA releaser amphetamine, and the 
      selective 5-HT releaser fenfluramine are used in the present discussion to 
      highlight the ability of MDMA to model the locomotor activation induced by the 
      interaction of DA and 5-HT. Furthermore, this review summarizes evidence to 
      suggest that the influence of 5-HT receptors on behavioral function is dependent 
      upon the specific neurochemical environment evoked by a given drug, specifically 
      discussed here with regard to the interaction between 5-HT and DA systems.
FAU - Bankson, M G
AU  - Bankson MG
AD  - Department of Pharmacology and Toxicology, University of Texas Medical Branch, 
      Galveston, Texas 77555-1031, USA.
FAU - Cunningham, K A
AU  - Cunningham KA
LA  - eng
GR  - DA 00260/DA/NIDA NIH HHS/United States
GR  - DA 006511/DA/NIDA NIH HHS/United States
GR  - DA 07287/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Adrenergic Uptake Inhibitors)
RN  - 0 (Hallucinogens)
RN  - 0 (Receptors, Serotonin)
RN  - 0 (Serotonin Agents)
RN  - 333DO1RDJY (Serotonin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Adrenergic Uptake Inhibitors/pharmacology
MH  - Animals
MH  - Dopamine/*metabolism
MH  - Hallucinogens/pharmacology
MH  - Humans
MH  - Hyperkinesis/chemically induced
MH  - Models, Biological
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Presynaptic Terminals/drug effects/metabolism
MH  - Receptors, Serotonin/*metabolism
MH  - Serotonin/*metabolism
MH  - Serotonin Agents/*pharmacology
RF  - 57
EDAT- 2001/05/18 10:00
MHDA- 2001/06/23 10:01
CRDT- 2001/05/18 10:00
PHST- 2001/05/18 10:00 [pubmed]
PHST- 2001/06/23 10:01 [medline]
PHST- 2001/05/18 10:00 [entrez]
PST - ppublish
SO  - J Pharmacol Exp Ther. 2001 Jun;297(3):846-52.